secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2023-01-03T23:59:59+00:00
Accession:  0001737287-23-000003
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Allogene Therapeutics EVP of R&D Rafael Amado resigns effective Dec 30, 2022
----------------------------------------------------------------------------

- Rafael G. Amado, Executive Vice President of Research and Development, resigned.
- Effective date of resignation: December 30, 2022.
- Resignation is to pursue another opportunity; no replacement named.
- Departure of top R&D executive may impact pipeline development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000003/0001737287-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000003/allo-20221227.htm
  HTML page:      https://secwatch.observer/filing/0001737287-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer